Veracyte Inc logo

VCYT - Veracyte Inc News Story

$46.91 0.0  0.0%

Last Trade - 04/03/21

Sector
Healthcare
Size
Mid Cap
Market Cap £2.26bn
Enterprise Value £2.01bn
Revenue £84.6m
Position in Universe 1752nd / 6647

BUZZ-Veracyte: Up on collaboration with Bayer to advance genomic test

Tue 22nd December, 2020 6:20pm
** Shares of diagnostics co  VCYT.O  rise 15.6% to $59.31 
    ** VCYT announces collaboration with Bayer AG  BAYGn.DE  to
advance its precision oncology program in thyroid cancer
 urn:newsml:reuters.com:*:nBw95Lphya
    ** Co says Bayer will offer testing with VCYT's Afirma
Xpression Atlas test to identify underlying genomic drivers
within tumors of patients with advanced thyroid cancer
    ** Bayer will provide testing at no cost to all eligible
patients when ordered by physician, regardless of final results
and treatment decision - co
    ** Says physicians of patients found to harbor NTRK gene
fusion - a kind of mutation which may drive tumor growth in some
cancer - will be alerted
    ** Cos expect program to launch in Q1 2021
    ** Up to Monday's close, stock had risen 83.7% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.